Compounds which inhibit leukocyte adhesion mediated by VLA-4

Details Compounds which inhibit leukocyte adhesion mediated by VLA-4 Compounds which inhibit leukocyte adhesion mediated by VLA-4

2005-06-07

2005-06-07

Raymond, Richard L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S352000, C514S001000, C546S304000, C546S307000, C546S329000, C546S345000

Reexamination Certificate

active

06903088

ABSTRACT:
Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, antherosclerosis. AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

REFERENCES:
patent: 4018913 (1977-04-01), Okamoto et al.
patent: 4018915 (1977-04-01), Okamoto et al.
patent: 4036955 (1977-07-01), Okamoto et al.
patent: 4041156 (1977-08-01), Okamoto et al.
patent: 4046876 (1977-09-01), Okamoto et al.
patent: 4055636 (1977-10-01), Okamoto et al.
patent: 4055651 (1977-10-01), Okamoto et al.
patent: 4070457 (1978-01-01), Okamoto et al.
patent: 4073914 (1978-02-01), Kikumoto et al.
patent: 4085057 (1978-04-01), Masuda et al.
patent: 4096255 (1978-06-01), Kikumoto et al.
patent: 4104392 (1978-08-01), Okamoto et al.
patent: 4438122 (1984-03-01), Holmwood et al.
patent: 4505910 (1985-03-01), Bagli
patent: 4518600 (1985-05-01), Holmwood et al.
patent: 4544402 (1985-10-01), Schnurbusch et al.
patent: 4559345 (1985-12-01), Gomarasca et al.
patent: 4672065 (1987-06-01), Spatz
patent: 4908368 (1990-03-01), Murase et al.
patent: 4959364 (1990-09-01), Mueller et al.
patent: 4992439 (1991-02-01), Meanwell
patent: 5030644 (1991-07-01), Baldwin et al.
patent: 5120734 (1992-06-01), Klausener et al.
patent: 5238934 (1993-08-01), Knüppel et al.
patent: 5278184 (1994-01-01), Artico et al.
patent: 5510332 (1996-04-01), Kogan et al.
patent: 5580868 (1996-12-01), Lunkenheimer et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 5814643 (1998-09-01), Duggan et al.
patent: 5861429 (1999-01-01), Sato et al.
patent: 5925644 (1999-07-01), Jakobi et al.
patent: 5942504 (1999-08-01), Grobelny
patent: 5955491 (1999-09-01), Sohda et al.
patent: 5962479 (1999-10-01), Chen
patent: 5972946 (1999-10-01), Murata et al.
patent: 6005117 (1999-12-01), Wehner et al.
patent: 2241149 (1977-07-01), None
patent: 2259224 (1978-01-01), None
patent: 26 55 636 (1977-06-01), None
patent: 19536891 (1997-04-01), None
patent: 19548709 (1997-07-01), None
patent: 19654483 (1998-01-01), None
patent: 19713000 (1998-10-01), None
patent: 0 288 176 (1988-10-01), None
patent: 0 147 211 (1989-07-01), None
patent: 0330506 (1989-08-01), None
patent: 0330506 (1989-08-01), None
patent: 0 526 348 (1993-02-01), None
patent: 0 535 521 (1993-04-01), None
patent: WO 92/16549 (1992-10-01), None
patent: WO 93/12809 (1993-07-01), None
patent: WO 96/01644 (1996-01-01), None
patent: WO 96/22966 (1996-08-01), None
patent: WO 97/23451 (1997-07-01), None
patent: WO 98/00395 (1998-01-01), None
patent: WO 98/33783 (1998-08-01), None
patent: WO 98/53817 (1998-12-01), None
patent: WO 99/06390 (1999-02-01), None
patent: WO 99/06391 (1999-02-01), None
patent: WO 99/06431 (1999-02-01), None
patent: WO 99/06432 (1999-02-01), None
patent: WO 99/06433 (1999-02-01), None
patent: WO 99/10312 (1999-03-01), None
patent: WO 99/10313 (1999-03-01), None
patent: WO 99/37605 (1999-07-01), None
patent: WO 99/37618 (1999-07-01), None
patent: WO 99/52898 (1999-10-01), None
Kascheres et al.,Chemical Abstract DN 85:177351, also cited as J. Org. Chem. 41/22,3546-9(1976).
Toniolo et al.,Chemical Abstract DN 77:5775, also cited as J. Chem, Soc., Pekin Transactions,1, Org. & Bio-org. Chem.,9/10,1178-81(1972).
Wyzsza et al.,Chemical Abstract DN 70:96568, also cited as Roczniki Chemii,42/10,1647-60(1968).
PubMed Abstract 12783578, also cited as Expert Opinion Ther. Targets,7/3,427-40(2003).
PubMed Abstract 1287626, also cited as Mol.Cell Neursci.,23/3,427-39(2003).
PubMed Abstract 12877819, also cited as Pulm. Pharmacol. Ther.,16/5,279-85(2003).
Chemical Abstract DN 85:177351, also cited as J. Org. Chem. 41/22,3546-9(1976).
Chemical Abstract DN 77:5775, also cited as J. Chem, Soc., Pekin Transactions,1, Org. & Bio-org. Chem.,9/10,1178-81(1972.
Chemical Abstract DN 70:96568, also cited as Roczniki Chemii,42/10,1647-60(1968).
PubMed Abstract 12876405, also cited as Int. Arch. Allergy Immunol.,31/3,153-63(2003).
Hladon, Buguslaw et al., In Vitro cytostatic activity of some amino acid 4-N-substituted cytosines,Arch. Immunol. Ther. Exp.(1992), 40(2), 145-50. (Abstract).
Hoffman, Seigfried; Schubert, Herman; Nitsche, Klaus, N-Pyrimidinylamino acids. III. N-(oxopyrimidinyl) derivatives of neutral amino acids, Z.Chem. (1972), 12(1) 21-2, CODEN:ZECEAL (Abstract).
Teranishi, Katsunori; Goto, Toshio, Synthesis and Chemiluminescense of Coelenterazine (Oplophorus Luciferin) analogs,Bull, Chem. Soc. Jpn. (1990), 63(11), 3132-40 , (Abstract).
Abraham, W.M., et al, “α4-Integrins Mediate Antigen-induced Late Bronchial Responses and Prolonged Airway Hyperresponsiveness in Sheep.”J. Clin. Invest.93: 776-787 (1994).
Bao, L., et al. “Correlation of VLA-4 integrin expression with metastatic potential in various human tumour cell lines.”Diff. 52: 239-246 (1993).
Baron, J.L., et al. “Surface Expression of α4 Integrin by CD4 T Cells is Required for Their Entry into Brain Parenchyma.”J. Exp. Med.177: 57-68 (1993).
Baron, J.L., et al. et al. “The Pathogenesis of Adeoptive Murine Autonimmune Diabetes Requires an Interaction between α4-Integrins and Vascular Cell Adhesion Molecule-1.”J. Clin. Invest.93: 1700-1708 (1994).
Burkly, L.C., et al. “Protection Against Adoptive Transfer of Autoimmune Diabetes Mediated Through Very Late Antigent-4 Integrin.”Diabetes. 43: 529-534 (1994).
Cybulsky, M.I. et al “Endothelial Expression of a Mononuclear Leukocyte Adhesion Molecule During Atherogenesis.”Science. 251: 788-791 (1991).
Elices, M.J., et al. “Expression and Functional Significance of Alternatively Spliced CS1 Fibronecting in Rheumatoid Arthritis Microvasculature.”J. Clin. Invest. 93: 405-416 (1994).
Elices, M.J., et al. “VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the CLA-4/Fibronectin Binding Site,”Cell. 60: 577-584 (1990).
Hamann, A., et al. “Role of α4-Integrins in Lymphocute Homing to Mucosal Tissues in Vivo.”J. Immunology, 152: 3283-3292 (1994).
Kawaguchi, S., et al. “VLA-4 Molecules on Tumor Cells Initiate an Adhesive Interaction with VCAM-1 Molecules on Endothelial Cell Surface.”Japenese J. Cancer Res.83: 1304-1316 (1992).
Lauri, D., et al. “Decreased adhesion to endothelial cells and matrix proteins of H-2Kbgene transfected tumour cells.”British J. Cancer. 68: 862-867 (1993).
Li, H., et al. “An Atherogenic Diet Rapidly Induces VCAM-1, a Cytokine-Regulatable Mononuclear Leeukocyte Adhesion Molecule, in Rabbit Aortic Endothelium.”Arterioscler. Thromb. 13(2): 197-204 (1993).
Mulligan, M.S., et al. “Role of β1, β2 Integrins and ICAM-1 in Lung Injury afer Deposition of IgG and IgA Immune Complexes.”J. Immunol. 150(6): 2407-2417 (1993).
Okarhara, II., et al. “Involvement of Very Late Activation Antigen 4 (VLA-4) and Vascular Cell Adhesion Molecule 1 (VCAM-1) in Tumor Necrosis Factor α Enhancement of Experimental Metastasis.”Can. Res. 3233-3236 (1994).
Osborn, L. “Leukocyte Adhesion to Endothelium in Inflammation.”Cell. 62: 3-6 (1990).
Paavonen, T., et al. “In Vivo Evidence of the Role of α4α1-VCAM-1 Interaction in Sarcoma, but not in Carcinoma Extravasation.”Int. J. Can.58: 298 (1994).
Paul, L.C.,et al. “Monoclonal Antibodies Against LFA-1 and VLA-4 Inhibit Graft Vasculitis in Rat Cardiac Allografts.”Transpl. Proceed. 25(1): 813-814 (1993).
Postigo, A.A., et al. “Increased Binding of Synovial T Lumphocytes from Rheumatoid Arthritis to Endothelial-Leukocyte Adhesion Molecule-1 (ELAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1).”J.

Affiliated with

Also associated with

Rating

Compounds which inhibit leukocyte adhesion mediated by VLA-4 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds which inhibit leukocyte adhesion mediated by VLA-4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds which inhibit leukocyte adhesion mediated by VLA-4 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3476984